May 5 |
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
|
Apr 24 |
Roivant Sciences: Cashing In On Vants And Ventures
|
Apr 2 |
Roivant announces $1.5B share buyback, positive Phase 2 data
|
Apr 2 |
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
|
Mar 27 |
Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck
|
Mar 26 |
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
|
Mar 18 |
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
|
Feb 14 |
The Analyst Landscape: 4 Takes On Roivant Sciences
|
Feb 14 |
Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
|
Feb 13 |
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
|